Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
8.96 USD | -2.50% | +3.56% | 0.00% |
Apr. 22 | Guggenheim Starts Coverage on Boundless Bio With Buy Rating, $24 Price Target | MT |
Apr. 22 | Piper Sandler Starts Audentes Therapeutics With Overweight Rating, $20 Price Target | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
0.00% | 205M | |
+17.96% | 123B | |
+14.86% | 107B | |
-4.64% | 24.01B | |
+2.27% | 22.59B | |
-10.09% | 18.16B | |
-41.04% | 16.84B | |
-12.41% | 16.23B | |
+2.78% | 13.43B | |
+24.19% | 11.32B |
- Stock Market
- Equities
- BOLD Stock
- News Boundless Bio, Inc.
- Piper Sandler Starts Audentes Therapeutics With Overweight Rating, $20 Price Target